Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Expression of the stem cell marker CD133 in malignant meningioma

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Brain tumor biomarkers for research, clinics, and registries - The 2021 Brain Tumor Epidemiology Consortium meeting report

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. VEGF-A mRNA measurement in meningiomas using a new simplified approach: branched DNA and chemiluminescence

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Health-Related Quality of Life and Return to Work after Surgery for Spinal Meningioma: A Population-Based Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Diagnostic Accuracy and Clinical Impact of [ 18F]FET PET in Childhood CNS tumors

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The stem cell marker CD133 has been sporadically investigated in meningioma, but because of the rarity of malignant meningioma (WHO grade III), only 7 malignant meningioma specimens have been included in previous studies. We investigated CD133 expression using the AC133 antibody clone in a consecutive cohort of 38 malignant meningiomas. Our results showed few, small CD133-positive hot spots with a pattern dominated by membranous staining and capping of the proteins without any nuclear CD133 staining in 30 of the 38 tumors. We could not corroborate spatial co-expression of hot spots with the proliferative marker, Ki-67, and CD133 hot spots in adjacent slides, nor did we find differences between Ki-67 expression in CD133-negative and -positive tumor specimens (Fisher's exact test: p = 0.69). CD13-positive niches represented only 0 - 1% of meningioma cells in most of the malignant meningioma, while CD133-positive cells were undetectable in 21% of the whole-section tumor samples. We found stem cell niches in 79% of malignant meningioma specimens in our cohort.

Original languageEnglish
JournalClinical Neuropathology
Volume40
Issue number3
Pages (from-to)151-159
Number of pages9
ISSN0722-5091
DOIs
Publication statusPublished - 2021

    Research areas

  • Malignant meningioma, – CD133, – heterogeneity, – hot spots, – Ki-67

ID: 61411755